Kathleen Gondek is currently the global head of evidence and outcomes at Takeda. She is responsible for developing and implementing global outcomes and epidemiology research strategies to establish the value proposition for Takeda products, from early development through commercialization. Her passion for bringing the patient voice into drug development and utilizing real-world data to inform decision making has contributed to growth in the pharmaceutical industry for more than 20 years.
Prior to joining Takeda, Kathleen held positions of increasing responsibility at Bayer that span a 15-year career with the organization. She has coauthored more than 50 peer-reviewed publications. She served as a member of the rare disease advisory panel at PCORI and is actively involved in cross-industry activities. Kathleen also serves as a board member for the Arts & Business Council of Greater Boston.
Kathleen holds a bachelor’s degree in pharmacy from the State University of New York at Buffalo and a Ph.D. in pharmacy practice and administrative science from the University of Maryland, Baltimore. While at Bayer, Kathleen was a lecturer at the Yale School of Public Health.